Technical Analysis for ICAD - icad inc.

Grade Last Price % Change Price Change
D 1.54 0.00% 0.00
ICAD closed unchanged on Friday, November 22, 2024, on 86 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish 0.00%
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%

   Recent Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

icad inc. Description

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy that enable healthcare professionals and radiologists to identify pathologies and pinpoint cancer earlier. It offers Axxent eBx system, which is used for the treatment of early stage breast cancer, endometrial cancer, and skin cancer, as well as for the treatment of other cancers or conditions where radiation therapy is indicated. It also provides computer-aided detection (CAD) solutions for digital and film-based mammography systems, including SecondLook systems that detects and identifies masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD analysis, and sends the CAD results to PACS and/or review workstations. In addition, the company offers image analysis and workflow solutions in MRI imaging comprising SpectraLook for breast, VividLook for prostate, and OmniLook for other organs; and VersaVue Enterprise, a review and reporting solution, which provides visual and quantitative depictions of the movement of contrast agent through a lesion. Further, it provides VeraLook that supports the detection of colonic polyps in conjunction with CT Colonography; and the TotalLook MammoAdvantage system, a mammography specific digitizer. The company sells its products to hospitals, ambulatory care centers, and free standing radiation oncology facilities. It sells its products directly, as well as through various original equipment manufacturer partners, distributors, and resellers worldwide. The company was founded in 1984 and is headquartered in Nashua, New Hampshire.


Classification

Sector: Technology
Industry: Software - Application
Keywords: Medicine Cancer Imaging Breast Cancer Radiation Treatment Of Breast Cancer Medical Imaging Radiation Therapy Polyp MRI Organs Workflow Solutions Cancer Screening Endometrial Cancer Mammography Skin Cancer Ambulatory Care Picture Archiving And Communication System Breast Imaging

Is ICAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.6499
52 Week Low 1.18
Average Volume 199,742
200-Day Moving Average 1.56
50-Day Moving Average 1.72
20-Day Moving Average 1.84
10-Day Moving Average 1.80
Average True Range 0.16
RSI (14) 40.48
ADX 24.14
+DI 21.54
-DI 28.76
Chandelier Exit (Long, 3 ATRs) 1.93
Chandelier Exit (Short, 3 ATRs) 1.94
Upper Bollinger Bands 2.34
Lower Bollinger Band 1.34
Percent B (%b) 0.2
BandWidth 54.19
MACD Line -0.05
MACD Signal Line 0.02
MACD Histogram -0.0665
Fundamentals Value
Market Cap 40.58 Million
Num Shares 26.4 Million
EPS -0.49
Price-to-Earnings (P/E) Ratio -3.14
Price-to-Sales 1.44
Price-to-Book 1.18
PEG Ratio -0.56
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.66
Resistance 3 (R3) 1.66 1.63 1.64
Resistance 2 (R2) 1.63 1.60 1.62 1.63
Resistance 1 (R1) 1.58 1.58 1.56 1.58 1.63
Pivot Point 1.55 1.55 1.54 1.54 1.55
Support 1 (S1) 1.50 1.52 1.49 1.50 1.45
Support 2 (S2) 1.47 1.50 1.47 1.45
Support 3 (S3) 1.42 1.47 1.44
Support 4 (S4) 1.42